Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBI-833/OBI-821 in esophageal cancer
NCT05376423Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of OBI-833 in esophageal cancer, sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
OBI-833
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT05376423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376423.